The pro- and anti-tumor role of ILC2s.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_ECAD6DCB8107
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
The pro- and anti-tumor role of ILC2s.
Périodique
Seminars in immunology
Auteur⸱e⸱s
Trabanelli S. (co-premier), Chevalier M.F. (co-premier), Derré L. (co-dernier), Jandus C. (co-dernier)
ISSN
1096-3618 (Electronic)
ISSN-L
1044-5323
Statut éditorial
Publié
Date de publication
02/2019
Peer-reviewed
Oui
Volume
41
Pages
101276
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
Group 2 innate lymphoid cells (ILC2s) are critical for the initiation of type 2 inflammatory diseases. However, ILC2s are also involved in the establishment of the immune microenvironment during tumor development, growth and metastasization. In this context, ILC2s have been shown to be either tumor-suppressive or tumor-promoting according to the tumor type, the cytokine secreted and the other immune cells that are, in turn, recruited and/or activated.
Mots-clé
Animals, Cytokines/metabolism, Disease Susceptibility, Humans, Immunity, Innate, Lymphocyte Subsets/immunology, Lymphocyte Subsets/metabolism, Lymphocytes/immunology, Lymphocytes/metabolism, Neoplasms/etiology, Neoplasms/metabolism, Neoplasms/pathology, Tumor Microenvironment/immunology, Cancer, Group-2 innate lymphoid cells, ILC2, Tumor immunoregulation
Pubmed
Web of science
Open Access
Oui
Création de la notice
14/06/2019 17:24
Dernière modification de la notice
30/07/2024 7:02
Données d'usage